Compare Otis Worldwide Corp (OTIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs BIO-TECHNE Corp — how do they compare? Otis Worldwide Corp trades at $70.61 (market cap $27.61B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Otis Worldwide Corp is far larger — about 2.5× BIO-TECHNE Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| OTIS | TECH | |
|---|---|---|
Market Cap | $27.61B | $11.16B |
Sector | Industrials | Health |
52-Week High | $100.99 | $72.12 |
52-Week Low | $69.34 | $43.31 |
Enterprise Value | $34.99B | $11.24B |
Dividend Yield | 2.36% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $71.95, down 2.04% recently, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates but showing strong service growth. Revenue trends are stable, with 2025 revenue at $14.43B and net income of $1.38B. Analyst consensus is a Buy with a $91.00 price target, implying significant upside. Recent news highlights modernization initiatives and Q2 earnings focus.
The outlook for OTIS is cautiously optimistic, with potential driven by service segment strength and strategic upgrades, but risks include margin pressures from tariffs and economic headwinds. Valuation at a P/E of 19.54 is reasonable, yet debt levels and recent earnings misses warrant monitoring. Institutional sentiment is mixed, with 38% Buy ratings offset by high debt-to-asset ratio of 75.54% as of 2025.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
